TOKYO -- The success of Daiichi Sankyo's blockbuster cancer drug Enhertu has helped propel it into the ranks of Japan's most valuable companies, lifting its market capitalization above 10 trillion yen ($64 billion) on rising growth expectations.
Pharmaceuticals
Daiichi Sankyo beats Honda in market cap on cancer drug ambitions
Japanese drugmaker eyes broader U.S. approval for blockbuster Enhertu
Daiichi Sankyo's booth at the American Society of Clinical Oncology annual meeting in Chicago. (Daiichi Sankyo)
Read Next
Latest on Pharmaceuticals
